What Ionis Investors Should Understand about Its Revenue Stream


Sep. 20 2016, Updated 6:04 p.m. ET

Ionis’s revenues

As discussed earlier, Ionis (IONS) reported revenues of $38.5 million in its 2Q16 results. This translates to a 68% decline from the $120.4 million in 2Q15. Further, analysts estimate that revenues will increase by over 100% to $114.8 million in 3Q16.

The above graph shows the Ionis revenues over the last five years.

Article continues below advertisement

Revenue performance

From the total revenues of ~$38.5 million for 2Q16, ~$15 million were received as upfront payment from Kastle Therapeutics for the acquisition of Kynamro. The revenues are reported under two segments:

  • research and development revenues under collaborative agreements
  • licensing and royalty revenues

Breakup of revenues

The research and development revenues under the collaborative agreements for 2Q16 were $22.4 million as compared to $119.7 million for 2Q15. The licensing and royalty revenues rose to $16.0 million for 2Q16 as compared to $0.8 million for 2Q15. The break-up of these revenues is as follows:

  • $15 million upfront payment from Kastle Therapeutics for global development and commercialization rights for Kynamro injection.
  • $2 million for progression in Nusinersen’s phase III study as well as Ionis-BIIB4RX received from Biogen (BIIB)
  • $21.4 million from amortization of upfront fees and manufacturing services performed for the company’s partners

Investors can consider ETFs like the iShares Nasdaq Biotech ETF (IBB), which holds ~0.6% of its total assets in Ionis, or the PowerShares Russell Midcap Pure Growth Portfolio (PXMG), which holds ~0.6% of its total assets in Ionis, in order to divest the risk. Apart from Ionis, IBB also holds 8.4% of its total assets in Amgen (AMGN), 8.2% in Gilead Sciences (GILD), 8.1% in Celgene (CELG), and 7.2% in Biogen (BIIB).


More From Market Realist

  • Businesswoman looking out a window
    Company & Industry Overviews
    Shifting Focus: Three Women Investing Funds in 2021
  • Aol logo on office building,
    Company & Industry Overviews
    What We Know About Apollo Global Management, New Owners of AOL and Yahoo
  • Chick-fil-A sign
    Company & Industry Overviews
    Why It Only Costs $10K to Own a Chick-fil-A Location
  • Beyond Meat Burger 3.0
    Company & Industry Overviews
    How Is Beyond Burger 3.0 Different and Will It Bring BYND Stock Up?
  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.